TY - JOUR
T1 - Association of Differential Mast Cell Activation with Granulocytic Inflammation in Severe Asthma
AU - Tiotiu, Angelica
AU - Badi, Yusef
AU - Kermani, Nazanin Zounemat
AU - Sanak, Marek
AU - Kolmert, Johan
AU - Wheelock, Craig E.
AU - Hansbro, Philip M.
AU - Dahlén, Sven-Erik
AU - Sterk, Peter J.
AU - U-BIOPRED Consortium Project Team
AU - Djukanovic, Ratko
AU - Guo, Yike
AU - Mumby, Sharon
AU - Adcock, Ian M.
AU - Chung, Kian Fan
AU - Hoda, Uruj
AU - Rossios, Christos
AU - Bel, Elisabeth
AU - Rao, Navin
AU - Myles, David
AU - Compton, Chris
AU - van Geest, Marleen
AU - Howarth, Peter
AU - Roberts, Graham
AU - Lefaudeux, Diane
AU - de Meulder, Bertrand
AU - Bansal, Aruna T.
AU - Knowles, Richard
AU - Erzen, Damijn
AU - Wagers, Scott
AU - Krug, Norbert
AU - Higenbottam, Tim
AU - Matthews, John
AU - Erpenbeek, Veit
AU - Carayannopoulos, Leon
AU - Roberts, Amanda
AU - Supple, David
AU - deBoer, Pim
AU - Caruso, Massimo
AU - Chanez, Pascal
AU - Horváth, Ildikó
AU - Musial, Jacek
AU - Sandström, Thomas
N1 - Funding Information: *Co–first authors. ‡Co–senior authors. A complete list of U-BIOPRED Consortium Project Team members may be found before the beginning of the REFERENCES. Supported by the European Union’s Seventh Framework Programme (FP7/2007-2013) Innovative Medicines Initiative Joint Undertaking (grant 115010). U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes) was also supported by European Federation of Pharmaceutical Industries and Associations companies’ in-kind contribution (www.imi.europa.eu). K.F.C. and I.M.A. are funded by UK Research and Innovation. K.F.C. is an Emeritus Senior Investigator of the UK National Institute for Health Research. P.M.H. is funded by the National Health and Medical Research Council of Australia. C.E.W. is funded by the Swedish Heart Lung Foundation (grants HLF 20180290 and HLF 20200693). Funding Information: Supported by the European Union?s Seventh Framework Programme (FP7/2007-2013) Innovative Medicines Initiative Joint Undertaking (grant 115010). U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes) was also supported by European Federation of Pharmaceutical Industries and Associations companies? in-kind contribution (www.imi.europa.eu). K.F.C. and I.M.A. are funded by UK Research and Innovation. K.F.C. is an Emeritus Senior Investigator of the UK National Institute for Health Research. P.M.H. is funded by the National Health and Medical Research Council of Australia. C.E.W. is funded by the Swedish Heart Lung Foundation (grants HLF 20180290 and HLF 20200693). Publisher Copyright: Copyright © 2022 by the American Thoracic Society.
PY - 2022/2/15
Y1 - 2022/2/15
N2 - Rationale: Mast cells (MCs) play a role in inflammation and both innate and adaptive immunity, but their involvement in severe asthma (SA) remains undefined. Objectives: We investigated the phenotypic characteristics of the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes) asthma cohort by applying published MC activation signatures to the sputum cell transcriptome. Methods: Eighty-four participants with SA, 20 with mild/moderate asthma (MMA), and 16 healthy participants without asthma were studied. We calculated enrichment scores (ESs) for nine MC activation signatures by asthma severity, sputum granulocyte status, and three previously defined sputum molecular phenotypes or transcriptome-associated clusters (TACs) 1, 2, and 3 using gene set variation analysis. Measurements and Main Results: MC signatures except unstimulated, repeated FceR1-stimulated and IFN-g–stimulated signatures were enriched in SA. A FceR1-IgE–stimulated and a single-cell signature from asthmatic bronchial biopsies were highly enriched in eosinophilic asthma and in the TAC1 molecular phenotype. Subjects with a high ES for these signatures had elevated sputum amounts of similar genes and pathways. IL-33– and LPS-stimulated MC signatures had greater ES in neutrophilic and mixed granulocytic asthma and in the TAC2 molecular phenotype. These subjects exhibited neutrophil, NF-kB (nuclear factor-kB), and IL-1b/TNF-a (tumor necrosis factor-a) pathway activation. The IFN-g–stimulated signature had the greatest ES in TAC2 and TAC3 that was associated with responses to viral infection. Similar results were obtained in an independent ADEPT (Airway Disease Endotyping for Personalized Therapeutics) asthma cohort. Conclusions: Gene signatures of MC activation allow the detection of SA phenotypes and indicate that MCs can be induced to take on distinct transcriptional phenotypes associated with specific clinical phenotypes. IL-33–stimulated MC signature was associated with severe neutrophilic asthma, whereas IgE-activated MC was associated with an eosinophilic phenotype.
AB - Rationale: Mast cells (MCs) play a role in inflammation and both innate and adaptive immunity, but their involvement in severe asthma (SA) remains undefined. Objectives: We investigated the phenotypic characteristics of the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes) asthma cohort by applying published MC activation signatures to the sputum cell transcriptome. Methods: Eighty-four participants with SA, 20 with mild/moderate asthma (MMA), and 16 healthy participants without asthma were studied. We calculated enrichment scores (ESs) for nine MC activation signatures by asthma severity, sputum granulocyte status, and three previously defined sputum molecular phenotypes or transcriptome-associated clusters (TACs) 1, 2, and 3 using gene set variation analysis. Measurements and Main Results: MC signatures except unstimulated, repeated FceR1-stimulated and IFN-g–stimulated signatures were enriched in SA. A FceR1-IgE–stimulated and a single-cell signature from asthmatic bronchial biopsies were highly enriched in eosinophilic asthma and in the TAC1 molecular phenotype. Subjects with a high ES for these signatures had elevated sputum amounts of similar genes and pathways. IL-33– and LPS-stimulated MC signatures had greater ES in neutrophilic and mixed granulocytic asthma and in the TAC2 molecular phenotype. These subjects exhibited neutrophil, NF-kB (nuclear factor-kB), and IL-1b/TNF-a (tumor necrosis factor-a) pathway activation. The IFN-g–stimulated signature had the greatest ES in TAC2 and TAC3 that was associated with responses to viral infection. Similar results were obtained in an independent ADEPT (Airway Disease Endotyping for Personalized Therapeutics) asthma cohort. Conclusions: Gene signatures of MC activation allow the detection of SA phenotypes and indicate that MCs can be induced to take on distinct transcriptional phenotypes associated with specific clinical phenotypes. IL-33–stimulated MC signature was associated with severe neutrophilic asthma, whereas IgE-activated MC was associated with an eosinophilic phenotype.
KW - Eosinophils
KW - IL-33
KW - IgE-FceRI
KW - Mast cell
KW - Neutrophils
UR - http://www.scopus.com/inward/record.url?scp=85124633452&partnerID=8YFLogxK
U2 - https://doi.org/10.1164/rccm.202102-0355OC
DO - https://doi.org/10.1164/rccm.202102-0355OC
M3 - Article
C2 - 34813381
SN - 1073-449X
VL - 205
SP - 397
EP - 411
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 4
ER -